Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck submits Erbitux indication extension to EMA for NSCLC treatment

APP voluntarily recalls Irinotecan Hydrochloride Injection for precautionary measure

APP voluntarily recalls Irinotecan Hydrochloride Injection for precautionary measure

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

PharmaEngine presents PEP02 phase II studies in gastric and pancreatic cancers at ASCO 2011

PharmaEngine presents PEP02 phase II studies in gastric and pancreatic cancers at ASCO 2011

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

Positive results from nimotuzumab Phase II study for gastric cancer

Positive results from nimotuzumab Phase II study for gastric cancer

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Celator, Cephalon extend cancer research agreement

Celator, Cephalon extend cancer research agreement

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Immunomedics announces additional claim for RS7 antibodies patent family

Immunomedics announces additional claim for RS7 antibodies patent family

Oncothyreon commences combination PX-866/cetuximab Phase 1/2 trial in cancers

Oncothyreon commences combination PX-866/cetuximab Phase 1/2 trial in cancers

Celator granted U.S. Patent covering CombiPlex technology platform

Celator granted U.S. Patent covering CombiPlex technology platform

Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea

Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth